

Information for Doctors

# Medicare criteria for rebate



Including guidelines for  
repeat testing | July 2021

[northwestpath.com.au](http://northwestpath.com.au)

Medicare rebates apply for most pathology tests. For some tests, Medicare requires that the patient satisfy specific clinical criteria in order to receive a rebate, or limits the frequency of testing, or both. Some tests do not qualify for a rebate under any circumstances.

A list of all up-to-date test criteria for Pathology Services is available at [mbsonline.gov.au](http://mbsonline.gov.au).

## Medicare criteria for rebates

Test	Rule
<b>Activated protein C resistance (APC)</b>	History of venous thromboembolism OR first-degree relative who has a proven defect
<b>Active B12 (holotranscobalamin)</b>	Only attracts a rebate if Vitamin B12 is low or equivocal
<b>Antithrombin (ATIII)</b>	History of venous thromboembolism OR first-degree relative who has a proven defect
<b>BCR-ABL PCR or FISH</b>	Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement, in the diagnosis and monitoring of patients with laboratory evidence of: <ul style="list-style-type: none"> <li>i) acute myeloid leukaemia; OR</li> <li>ii) acute promyelocytic leukaemia; OR</li> <li>iii) acute lymphoid leukaemia; OR</li> <li>iv) chronic myeloid leukaemia</li> </ul>
<b>Bile acids</b>	3 tests in a pregnancy
<b>Brain natriuretic peptide (NT-ProBNP)</b>	Diagnosis of heart failure in patients presenting with dyspnoea to a hospital Emergency Department
<b>BRCA gene test (in treatment)</b>	Requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme (PBS) Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for whom testing of tumour tissue is not feasible
<b>BRCA gene test (diagnostic and predictive)</b>	Requested by a consultant physician (geneticist or oncologist) Characterisation of germline gene mutations, including copy number variation in BRCA1 and BRCA2 genes and one or more of the following genes: STK11, PTEN, CDH1, PALB2, or TP53, where the patient: <ul style="list-style-type: none"> <li>i) has breast or ovarian cancer, for whom clinical and family history criteria, as assessed by the requesting specialist or consultant physician using a quantitative algorithm, place the patient at &gt;10% risk of having a pathogenic mutation identified in one or more of the genes specified above; OR</li> <li>ii) is a biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes specified above, and has not previously received a service under item 73296</li> </ul>
<b>C-telopeptide (CTX)</b>	Monitoring of patients with proven low bone mineral density
<b>Cervical screening test (CST)</b>	
<b>CST routine (HPV)</b>	<ul style="list-style-type: none"> <li>▪ Asymptomatic screening</li> <li>▪ Aged 25 years and over</li> <li>▪ 1 test in a 57-month period</li> </ul>
<b>Co-test (HPV+LBC)</b>	Medicare rebate only applies where the patient: <ul style="list-style-type: none"> <li>i) is symptomatic (provide details of symptoms); OR</li> <li>ii) is DES exposed; OR</li> <li>iii) requires Test of Cure (previous HSIL); OR</li> <li>iv) requires follow-up (previous AIS) or cervical cancer</li> </ul> Any age, no time restriction
<b>HPV test</b>	Medicare rebate only applies where the patient: <ul style="list-style-type: none"> <li>i) requires follow-up 12-month repeat test; OR</li> <li>ii) is immune-deficient; OR</li> <li>iii) has experienced early sexual debut (&lt;14yrs) prior to vaccination (1 test between 20–24yrs of age); OR</li> <li>iv) received previous unsatisfactory HPV test (must have previous cervical MBS screening item)</li> </ul>
<b>LBC test</b>	Medicare rebate only applies following: <ul style="list-style-type: none"> <li>i) HPV detection in a self-collected sample; OR</li> <li>ii) previous unsatisfactory LBC test (must have previous cervical MBS screening item) ; OR</li> <li>iii) previous endometrial/extruterine cancer</li> </ul>

Test	Rule
<b>Cervical screening test (CST)</b>	
Vaginal co-test (HPV+LBC)	Medicare rebate only applies following: i) hysterectomy and previous HSIL (Test of Cure not complete prior to hysterectomy); OR ii) previous AIS; OR iii) patient experiencing symptoms; OR iv) HPV detection
Vaginal HPV test	Medicare rebate only applies following: i) previous hysterectomy without evidence of cervical pathology; OR ii) previous hysterectomy screening history unknown; OR iii) previous unsatisfactory vaginal HPV test (must have previous vaginal MBS screening item)
Vaginal LBC test	Previous unsatisfactory vaginal LBC test (must have previous vaginal MBS screening item)
Vaginal self-collected HPV test	Medicare rebate only applies where the patient: i) is under or never screened and refuses speculum exam (at least 30yrs of age and never screened or at least 2 years overdue for screening (1 test per 84 months)); OR ii) requires self-collect follow-up 12-month repeat test (only claimable within 21 months of HPV detected result in a self-collected sample)
<b>Colorectal cancer gene panel (incl. KRAS, NRAS, BRAF, PIK3CA)</b>	Requested by a specialist or consultant physician A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV) to determine if the requirements relating to rat sarcoma oncogene (RAS) gene mutation status for access to cetuximab or panitumumab under the PBS are fulfilled, if: i) the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; OR ii) a RAS mutation is found
<b>Copper (Cu), Zinc (Zn), Selenium (Se), Manganese (Mn), Aluminium (Al), Arsenic (As), Beryllium (Be), Cadmium (Cd), Chromium (Cr), Gold (Au), Mercury (Hg), Nickel (Ni) or Strontium (Sr)</b>	3 tests in a 6-month period
<b>Cystic fibrosis CFTR gene test (carrier screening)</b>	Requested by a specialist or consultant physician Testing for pathogenic variants: i) in a prospective parent whose fetus has ultrasonic findings of echogenic gut, in order to determine the risk of their fetus having cystic fibrosis or a CFTR-related disorder; OR ii) to determine the reproductive risk of a patient because their reproductive partner is already known to have a pathogenic CFTR variant
<b>Cystic fibrosis CFTR gene test (carrier screening)</b>	Requested by a GP or specialist Testing to determine if a patient is a genetic carrier of disease-causing variants previously laboratory identified in their family. The patient must have a personal risk of being a carrier of at least 6% (this includes family relatedness of parents, children, full-siblings, half-siblings, grandparents, grandchildren, aunts, uncles, first cousins, and first cousins once-removed, but excludes relatedness of second cousins or more distant relationships)
<b>Cystic fibrosis CFTR gene test (diagnostic)</b>	Requested by a specialist or consultant physician Testing for pathogenic variants where the patient has clinical or laboratory findings suggesting there is a high probability of cystic fibrosis or a CFTR-related disorder
<b>Cystic fibrosis CFTR gene test (full mutation panel)</b>	Requested by a specialist only on specific request, following consultation with the laboratory
<b>Deoxyypyridinoline cross-links (urinary DPD)</b>	Quantitation of products of collagen breakdown or formation for the monitoring of patients with proven low bone mineral density
<b>Eosinophil cationic protein (ECP)</b>	3 tests in a 12-month period for monitoring the response to therapy in corticosteroid treated asthma in a child <12yrs of age
<b>Factor V Leiden (FVL) PCR</b>	Proven DVT/PE in patient OR presence of mutation in first-degree relative
<b>Faeces culture</b>	1 test in a 7-day period
<b>Faeces ova, cysts and parasites</b>	2 tests in a 7-day period
<b>Familial adenomatous polyposis panel (genetic test)</b>	Characterisation of germline gene variants, including copy number variation, in the APC and MUTYH genes, requested by a specialist or consultant physician, for a patient: ▪ who has adenomatous polyposis; and ▪ who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having either of the following, on the basis of clinical and family history criteria: i) familial adenomatous polyposis; ii) MUTYH-associated polyposis

Test	Rule
<b>Familial hypercholesterolaemia panel (FH) (genetic test)</b>	<p>Requested by a specialist or consultant physician</p> <ul style="list-style-type: none"> <li>Characterisation of germline variants causing familial hypercholesterolaemia (which must include the LDLR, PCSK9 and APOB genes) for a patient for whom no familial mutation has been identified; and who has any of the following: a Dutch Lipid Clinic Network score of at least 6; an LDL-cholesterol level of at least 6.5 mmol/L in the absence of secondary causes; an LDL-cholesterol level of between 5.0 and 6.5 mmol/L with signs of premature or accelerated atherogenesis</li> <li>Detection of a familial mutation for a patient who has a first- or second-degree relative with a documented pathogenic germline gene variant for familial hypercholesterolaemia</li> <li>Maximum once per lifetime</li> </ul>
<b>Familial non-adenomatous polyposis panel (genetic test)</b>	<p>Characterisation of germline gene variants, including copy number variation, in the SMAD4, BMPR1A, STK11 and GREM1 genes, requested by a specialist or consultant physician, for a patient:</p> <ul style="list-style-type: none"> <li>who has non-adenomatous polyposis; and</li> <li>who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having any of the following, on the basis of clinical and family history criteria: <ul style="list-style-type: none"> <li>juvenile polyposis syndrome;</li> <li>Peutz-Jeghers syndrome;</li> <li>hereditary mixed polyposis syndrome</li> </ul> </li> </ul>
<b>First trimester screen</b>	1 test in a pregnancy
<b>Fragile X gene test</b>	Patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMR1 mutation OR the patient has a relative with a FMR1 mutation
<b>Free thyroxine (FT4) or Free triiodothyronine (FT3)</b>	<p>Medicare rebate only applies if any of the following criteria are written in clinical notes:</p> <ul style="list-style-type: none"> <li>TSH is abnormal</li> <li>Monitoring thyroid disease</li> <li>Psychiatric investigations or dementia</li> <li>Infertility investigation or amenorrhoea</li> <li>Investigating sick euthyroid syndrome in an admitted patient</li> <li>Pituitary dysfunction suspected</li> <li>On drugs interfering with thyroid function</li> </ul>
<b>Fructosamine</b>	4 tests in a 12-month period for established diabetes
<b>Haemochromatosis (HFE)</b>	<p>Detection of C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where the patient:</p> <ul style="list-style-type: none"> <li>has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; OR</li> <li>has a first-degree relative with haemochromatosis; OR</li> <li>has a first-degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis</li> </ul>
<b>HbA<sub>1c</sub> (in diagnosed diabetes)</b>	4 tests in a 12-month period
<b>HbA<sub>1c</sub> (in pregnancy)</b>	6 tests in a 12-month period
<b>HbA<sub>1c</sub> (screening)</b>	1 test in a 12-month period for diagnosis of diabetes in asymptomatic patients at high risk
<b>Hepatitis B PCR (quantitative) (viral load)</b>	<p>Hepatitis B carrier and not on treatment – 1 test in a 12-month period</p> <p>Hepatitis B carrier and on treatment – 4 tests in a 12-month period</p>
<b>Hepatitis C PCR genotype</b>	<ul style="list-style-type: none"> <li>Patient is Hepatitis C PCR positive AND being evaluated for antiviral therapy for chronic Hepatitis C</li> <li>1 test in a 12-month period</li> </ul>
<b>Hepatitis C PCR (qualitative) (diagnostic)</b>	<ul style="list-style-type: none"> <li>Patient is Hepatitis C seropositive; OR</li> <li>Patient's serological status is uncertain after testing; OR</li> <li>The test is performed for the purpose of: <ul style="list-style-type: none"> <li>determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; OR</li> <li>the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient</li> </ul> </li> <li>1 test in a 12-month period</li> </ul>
<b>Hepatitis C PCR (quantitative) (viral load)</b>	<ul style="list-style-type: none"> <li>Pre-treatment evaluation or assessment of efficacy of antiviral therapy of a patient with chronic Hepatitis C – 1 test in a 12-month period</li> <li>Patient undertaking antiviral therapy for Hepatitis C – 4 tests in a 12-month period</li> </ul>
<b>Hepatitis D antibody</b>	Hepatitis B positive patient
<b>Holter monitoring (ambulatory ECG)</b>	<ul style="list-style-type: none"> <li>Continuous electrocardiogram recording of ambulatory patient for 12 or more hours with interpretation and report, by a specialist or consultant physician, if the service is indicated for the evaluation of a patient for: <ul style="list-style-type: none"> <li>syncope; OR</li> <li>pre-syncopal episodes; OR</li> <li>palpitations, where episodes are occurring greater than once a week; OR</li> <li>another asymptomatic arrhythmia is suspected with an expected frequency of greater than once a week; OR</li> <li>surveillance following cardiac surgical procedures that have an established risk of causing dysrhythmia</li> </ul> </li> <li>1 test in a 4-week period</li> <li>The service does not apply if the patient is an admitted patient</li> </ul>

Test	Rule
IgE	2 tests in a 12-month period
JAK2 Exon 12 mutation or MPL PCR	Characterisation of mutations in: <ul style="list-style-type: none"> <li>i) the JAK2 gene; OR</li> <li>ii) the MPL gene; OR</li> <li>iii) both genes; in the diagnostic work-up, by, or on behalf of, the specialist or consultant physician, of a patient with clinical and laboratory evidence of polycythaemia vera or essential thrombocythaemia</li> </ul>
Lead	3 tests in a 6-month period
Lipoprotein EPG	<ul style="list-style-type: none"> <li>▪ If cholesterol is &gt;6.5 mmol/L and triglyceride &gt;4.0 mmol/L; or</li> <li>▪ In the diagnosis of types III and IV hyperlipidaemia</li> <li>▪ 2 tests in a 12-month period</li> </ul>
Lynch syndrome panel (genetic test)	Characterisation of germline gene variants, including copy number variation, in the MLH1, MSH2, MSH6, PMS2 and EPCAM genes, requested by a specialist or consultant physician, for: <ul style="list-style-type: none"> <li>▪ a patient with suspected Lynch syndrome following immunohistochemical examination of neoplastic tissue that has demonstrated loss of expression of one or more mismatch repair proteins; OR</li> <li>▪ a patient: <ul style="list-style-type: none"> <li>i) who has endometrial cancer; and</li> <li>ii) who is assessed by the specialist or consultant physician as being at a risk of more than 10% of having Lynch syndrome, on the basis of clinical and family history criteria</li> </ul> </li> </ul>
Methylene tetrahydrofolate reductase (MTHFR) gene mutation	Proven DVT/PE in patient OR presence of mutation in first-degree relative
Procollagen type 1 intact N-terminal propeptide (P1NP)	For test(s) performed for the monitoring of patients with metabolic bone disease or Paget's disease of the bone
Protein C	History of venous thromboembolism OR first-degree relative who has a proven defect
Protein EPG	1 test in a 28-day period
Protein S	History of venous thromboembolism OR first-degree relative who has a proven defect
Prothrombin gene mutation (PGM) PCR	Proven DVT/PE in patient OR presence of mutation in first-degree relatives
PSA-total (in diagnosed prostatic disease)	No limit
PSA-total (screening)	1 test in a 12-month period
Quantiferon TB Gold	A test of cell-mediated immune response in blood for the detection of latent tuberculosis by interferon gamma release assay (IGRA) in a patient: <ul style="list-style-type: none"> <li>i) who has been exposed to a confirmed case of active tuberculosis; OR</li> <li>ii) who is infected with human immunodeficiency virus; OR</li> <li>iii) who is to commence, or has commenced, tumour necrosis factor (TNF) inhibitor therapy; OR</li> <li>iv) who is to commence, or has commenced, renal dialysis; OR</li> <li>v) with silicosis; OR</li> <li>vi) who is, or is about to become, immunosuppressed because of disease or a medical treatment not mentioned in (i) to (v)</li> </ul>
RAST (specific IgE) in vitro allergy	4 episodes in a 12-month period and a maximum of 4 tests per episode
Red cell folate	When serum folate is persistently low, test is reflexed
Thrombophilia	History of venous thromboembolism OR first-degree relative who has a proven defect of Antithrombin (ATIII), FVL & PGM, Protein C, Protein S, or APC Resistance and testing for that defect only <b>Please note:</b> This is not an 'Acceptable Group Test' for Medicare purposes. To receive a Medicare rebate, the tests within this group must be ordered individually
Tumour markers - AFP; CA 15-3; CA 125; CA 19-9; CEA; βhCG; NSE; thyroglobulin	<ul style="list-style-type: none"> <li>▪ Monitoring of malignancy, or in the detection or monitoring of hepatic tumours, gestational trophoblastic disease, or germ cell tumour</li> <li>▪ Maximum of 2 tests per episode</li> </ul>
Urine drug screen (in rehabilitation)	36 tests in a 12-month period for monitoring a drug abuse treatment program at a rehabilitation centre
Urine drug screen (medical)	<ul style="list-style-type: none"> <li>▪ Patients participating in a drug abuse treatment program</li> <li>▪ Patients undergoing sleep studies</li> <li>▪ Patients undergoing treatment of psychiatric disorders</li> </ul>

Test	Rule
<b>Vitamins A, B1, B2, B3, B6, C &amp; E</b>	1 test for 1 or more vitamins in a 6-month period
<b>Vitamin B12</b>	1 test in a 12-month period
<b>Vitamin D [25-hydroxyvitamin D (25OHD)]</b>	<p>A test for routine Vitamin D status where the patient:</p> <ul style="list-style-type: none"> <li>i) has signs or symptoms of osteoporosis or osteomalacia; OR</li> <li>ii) has increased alkaline phosphatase and otherwise normal liver function tests; OR</li> <li>iii) has hyperparathyroidism, hypo- or hypercalcaemia, or hypophosphataemia; OR</li> <li>iv) is suffering from malabsorption (e.g. because the patient has cystic fibrosis, short bowel syndrome, inflammatory bowel disease or untreated coeliac disease, or has had bariatric surgery); OR</li> <li>v) has deeply pigmented skin, or chronic and severe lack of sun exposure for cultural, medical, occupational or residential reasons; OR</li> <li>vi) is taking medication known to decrease 25OHD levels (e.g. anticonvulsants); OR</li> <li>vii) has chronic renal failure or is a renal transplant recipient; OR</li> <li>viii) is &lt;16yrs of age and has signs or symptoms of rickets; OR</li> <li>ix) is an infant whose mother has established vitamin D deficiency; OR</li> <li>x) has a sibling who is &lt;16yrs of age with a vitamin D deficiency; OR</li> <li>xi) is an exclusively breastfed baby and has at least one other risk factor mentioned in (i) to (x)</li> </ul>

Please note that this list is not comprehensive and criteria may change at anytime.

#### Circumstances where Medicare rebate never applies:

- Screening for employment purposes – including pre-employment and WH&S testing
- Testing for court purposes
- Workers' compensation
- Insurance testing
- Immigration/visa testing
- Screening of sports people – including serology for boxing medicals
- Surveillance of sports people and athletes for performance-improving substances
- Screening of IVF donors
- Testing for non-therapeutic cosmetic surgery
- Detection of nicotine and metabolites in smoking withdrawal programs

# Medicare guidelines for repeat testing

## Drugs entitlement for patient having 6 visits within 6 months

Test requested	Accepted drug treatment - Brand name (generic name)		
<b>FBC (&amp; if requested ESR)</b>	Actemra (Tocilizumab) Adcetris (Brentuximab) Abemaciclib Afinitor (Everolimus) Alectinib (Alecensa) Anastrozole Antineoplastic treatment Anzatax (Paclitaxel) Arimidex (Anastrozole) Arava/Arabloc (Leflunomide) Aromasin (Exemestane) Atgam (Lymphocyte immune globulin) Aubagio (Teriflunomide) Avastin (Bevacizumab) Avelumab Azamun (Azathioprine) Azathioprine Betaferon/Roferon-A/Rebif (Interferon) Calquence (Acalabrutinib) Celebrex (Celecoxib) CellCept/Myfortic (Mycophenolate) Cetuximab Chemotherapy Cicloral/Neoral (Cyclosporin) Cimzia (Certolizumab) Clozaril/Clopine (Clozapine) Cosentyx (Secukinumab) Cosudex (Bicalutamide) Crizotinib Cycloblastin (Cyclophosphamide) Cyclosporin Cytotoxic therapy D-penammine (Penicillamine) Dabrafenib Doxorubicin Eculizumab Eligard Enbrel (Etanercept) Erbix (Cetuximab) Everolimus	Faslodex (Fulvestrant) Fludara (Fludarabine) Gilenya (Fingolimod) Glivec (Imatinib) Gold Herceptin (Trastuzumab) Humira (Adalimumab) Hydrea (Hydroxyurea) Ibrance (Palbociclib) Imbruvica (Ibrutinib) Imuran (Azathioprine) Interferon Jakavi (Ruxolitinib) Kadcyla (Trastuzumab) Keytruda (Pembrolizumab) Kisqali (Ribociclib) Leukeran (Chlorambucil) Mabthera (Rituximab) Mekinist (Trametinib) Mesasal (Mesalazine) Mesothelioma treatment Methoblastin (Methotrexate) Methotrexate Mitomycin Myfortic (Mycophenolate) Myleran (Busulfan) Myocrisin (Aurothiomalate) Obinutuzumab Ocrelizumab Olaparib Opdivo (Nivolumab) Orencia (Abatacept) Panafcort (Prednisone) Plaquenil (Hydroxychloroquine) Pomalyst (Pomalidomide) Prednisone Purinethol/6MP (Mercaptopurine) Pyralin/Salazopyrin (Sulfasalazine) Ramucirumab	Rapamune (Sirolimus) Regorafenib Remicade (Infliximab) Revlimid (Lenalidomide) Ridaura (Auranofin) Rinvoq (Upadacitinib) Sandimmun (Cyclosporin) Simponi (Golimumab) Stelara (Ustekinumab) Tacrolimus Tamoxifen Tarceva (Erlotinib) Tecentriq (Atezolizumab) Tecfidera (Dimethyl fumarate) Tagrisso (Osimertinib) Taxol (Paclitaxel) Temodal (Temozolomide) Thalomid (Thalidomide) Thioprine 50 (Azathioprine) Thiotepa Tilodene (Ticlopidine) Tysabri (Natalizumab) Upadacitinib Vectibix (Panitumumab) Velcade (Bortezomib) Ventoclox Verzenio (Abemaciclib) Vidaza (Azacitidine) Vinorelbine tartrate Votrient (Pazopanib) Xalkori (Crizotinib) Xelabine (Capecitabine) Xeljanz (Tofacitinib) Xeloda (Capecitabine) Xtandi (Enzutatamide) Yervoy (Ipilimumab) Zinbryta (Daclizumab) Zoladex (Goserelin) Zytiga (Abitarone)
<b>FBC, ESR, CRP, BIO, MBA, EUC, LFT &amp; if requested Gluc, Mg, CK, Chol/Trig</b>	Methotrexate, Arava/Arabloc (Leflunomide), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab), Gilenya (Fingolimod), Orencia (Abatacept), Aubagio (Teriflunomide), Actemra (Tocilizumab), Xeljanz (Tofacitinib), Simponi (Golimumab), Olumiant (Baricitinib), Rinvoq (Upadacitinib)		
<b>EUC</b>	Dialysis patients, Cicloral (Cyclosporin), Cisplatin		
<b>Lithium</b>	Lithium, Quilonum		
<b>Calcium (Ca<sup>2+</sup>), Albumin</b>	Vitamin D or Vit D Metabolite/Analogue, Calcitriol/Rocaltrol/Citrihexal/Kosteo/Sical/Calcijex (Calcitriol) for Osteoporosis, Xgeva (Denosumab)		
<b>UEC, Ca, Mg, Phos/PO<sub>4</sub> (CMP)</b>	Cancer patient receiving biphosphonate infusion Pamisol/Aredia (Pamidronate bisodium), Bondronat (Ibandronate), Zometa/Aclasta (Zolendronic acid)		

## Drugs entitlement for patient having unlimited visits within 6 months

Test requested	Accepted drug treatment
<b>INR or Prothrombin ratio</b>	Anticoagulant therapy: Clexane (Enoxaparin), Coumadin/Marevan (Warfarin), Dindevin (Phenindione), Coperin/Seprin (Heparin), Orgaran (Danaparoid)

